【摘要】 目的分析晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)石蜡包埋组织中错配切除修复蛋白(excisionrepaircrosscomplement-1,ERCC-1)与顺铂化疗敏感性的关系,并观察这些指标与患者生存的关系。方法收集广西医科大学附属肿瘤医院2000年2月1日~2004年6月30日经病理组织学诊断的晚期NSCLC患者(包括术后复发或不能手术)的病理标本,采用免疫组化SupervisionTM方法检测ERCC-1的表达,并将患者的疗效和生存资料与上述指标的表达进行比较。结果在51例病理组织中ERCC-1阳性33例,阳性率为64.7%(33/51)。ERCC-1阳性组化疗有效率为42.4%(14/33),阴性组有效率为72.2%(11/18),两者比较差异有统计学意义,χ2=4.151,P=0.042。ERCC-1阳性组平均生存期为9.3个月,阴性组为12.5个月,两组比较差异有统计学意义,χ2=5.61,P=0.018。ERCC-1阳性组1年生存率为30.3%(10/33),阴性组为72.2%(13/18),两组比较差异有统计学意义,χ2=8.267,P=0.004。结论ERCC-1对化疗疗效及生存的预测为负相关,可以作为晚期NSCLC含铂方案化疗敏感性及生存预测的指标。更多还原

【Abstract】 OBJECTIVE:To determine the predictive value of excision repair cross complement-1 (ERCC-1) expression and the sensitivity of cisplatin-based chemotherapy in advance non-small cell lung cancer (NSCLC). METHODS: From February 1,2000 to June 30,2004, 51 specimens of paraffin-embedded tissues of pathologically confirmed advanced NSCLC were studied. All patients received cisplatin contained regimen chemotherapy. The expression of ERCC-1 in tumor samples was examined by the immunohistochemical supervisiontm method. The response rates and survival data were analyzed according to the over-expression or not of the parameter. RESULTS: In these 51 patients, over expression rates of ERCC-1 was 64.7%(33/51). The response rate of cisplatin-based chemotherapy in negative group and over expression group of ERCC-1 were 72.2% and 42.4% respectively,being a significant difference (χ2=4.151, P=0.042). The average survival time in negative group and over-expression group were 12.5 and 9.3 months for ERCC-1, being a significant difference ( χ2= 5.61, P=0.018). The 1-year survival time in negative group and over-expression group were 72.2% and 30.3% for ERCC-1, being a significant diference (χ2=8.267, P=0.004). CONCLUSION: ERCC-1 can be used as a molecular marker of cisplatin sensitivity and prognosis in advanced NSCLC patients.更多还原